Why Is CELLDEX THERAPEUTICS (CLDX) Stock Down Today?

Celldex Therapeutics (CLDX) fell 6.28% to $35.90 in early trading on Monday driven by the filing of an SEC 8-K disclosing the departure or appointment of certain officers. The document highlighted changes in executive compensation arrangements, which has raised questions among investors about leadership stability and strategic direction.

What Happened

The stock opened at $38.07, a modest 0.6% gap down from the prior close, but quickly declined to a session low of $35.67 within 15 minutes of the open. The SEC filing, dated July 15, included details about the departure of directors or certain officers and related compensatory arrangements. While the filing itself does not specify the names of those involved, it is likely linked to the broader context of Celldex's leadership changes. Separately, Benzinga reported that CFO Sam Martin plans to retire in 2027, adding to the narrative of executive transition. The stock closed the session at $35.90 with a volume of 0.1 million shares, which is 0.1 times the 3-month average.

What The Data Shows

Celldex remains unprofitable with a trailing twelve-month (TTM) earnings per share (EPS) of -4.27 and TTM revenue down 88.6%. The stock has traded between $19.72 and $40.30 over the past 52 weeks. Despite recent positive clinical data from its Barzolvolimab and CDX-622 programs, the stock has underperformed in recent weeks, with sentiment trending lower, dropping from a 30-day average of 57/100 to 50/100 over the last seven days. The stock’s beta of 0.90 suggests it is slightly less volatile than the broader market.

What To Watch

Investors should continue to monitor Celldex’s leadership developments and any upcoming corporate actions. The company is scheduled to highlight further data from its clinical programs at the EAACI Annual Congress 2026, which may influence investor sentiment in the coming weeks.